When Pharma Merges, R&D Is the Dowry

See allHide authors and affiliations

Science  17 Mar 2000:
Vol. 287, Issue 5460, pp. 1952-1953
DOI: 10.1126/science.287.5460.1952

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Pharmaceutical companies' continuing quest to get bigger is not just megalomania. Although no company has even a double-digit slice of the global prescription drug market, each must have enough market share and product lines to maintain a significant presence in the United States, Europe, and Japan. Staying on top also requires doing more and better research, both to take advantage of new opportunities and to cover the continuing rise in the cost of developing new drugs.